City

New York (1)

Seoul (1)

Condition

Hypopharynx (2)

Larynx (2)

Oropharynx (2)

Squamous Cell Carcinoma of the Oral Cavity (1)

Stage II-IVB Operable HNSCC Oral Cavity (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Icahn School of Medicine at Mount Sinai (1)

Yonsei University (1)

Collaborator

William Marsh Rice University (1)

Intervention

durvalumab (1)

durvalumab + tremelimumab (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (2)

Study Type

Interventional (1)

Observational (1)

hypopharynx

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx Trial in Seoul (Durvalumab, durvalumab + tremelimumab)

Recruiting

Stage II-IVB Operable HNSCC Oral Cavity
+3 more

Durvalumab
durvalumab + tremelimumab

Seoul, Korea, Republic of

Yonsei University Health System, Severance Hospital

Apr 22, 2021

Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium

Completed

Squamous Cell Carcinoma of the Oral Cavity
+3 more

New York, New York

Mount Sinai School of Medicine

Jun 20, 2012